Genentech Inc.

Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes (2021) Kiner E, Willie E, Schmutz H, Chandler J, Schnell A, Thakore PI, LeGros G, et al. Journal article Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC) (2021) Hurvitz SA, Fasching P, Park YH, Quiroga V, Crnjevic TB, Fresco R, Lopez-Valverde V, et al. Conference contribution Comparison of genome-wide gene expression profiling by rna sequencing versus microarray in bronchial biopsies of copd patients before and after inhaled corticosteroid treatment: Does it provide new insights? (2021) Ditz B, Boekhoudt JG, Aliee H, Theis FJ, Nawijn M, Brandsma CA, Hiemstra PS, et al. Journal article Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study (2021) Hurvitz SA, Park YH, Bardia A, Quiroga V, Lopez-Valverde V, Steinseifer J, Moore HM, et al. Conference contribution Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial (2021) Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, et al. Journal article TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL (2020) Stone JH, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial (2019) Stone J, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial (2019) Stone J, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial (2019) Stone J, Han J, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution